What are cancer patients willing to pay for prophylactic epoetin alfa?--A cost-benefit analysis.
Orhan
B
B
Yalçin
S
S
D000740:Anemia / Q000517:prevention & control; D000970:Antineoplastic Agents / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa